Christian Buske

This study tests a drug called obinutuzumab in 56 people with newly diagnosed marginal zone lymphoma who cannot have or have failed local therapy. The goal is to see if this antibody can shrink tumors and control the disease without the harsh side effects of chemotherapy. Partici…

This study tests whether adding carfilzomib to the standard drug ibrutinib can improve remission rates in people with Waldenström's macroglobulinemia, a slow-growing blood cancer. About 99 participants will receive either the combination or ibrutinib alone. The goal is to see if …

This study tests a chemotherapy-free combination of three drugs (bortezomib, rituximab, and ibrutinib) as a first treatment for people with Waldenström's macroglobulinemia, a rare blood cancer. The goal is to see if this approach can keep the disease from getting worse for at lea…

This study tests a new drug combination (Copanlisib and Rituximab) for people with marginal zone lymphoma, a slow-growing blood cancer. The goal is to see if this chemotherapy-free approach can shrink tumors as well as standard chemo but with fewer side effects. The trial include…